2025
Efficacy and toxicity profile of antibody-drug conjugate (ADC) based combination therapy in patients with advanced urothelial carcinoma (aUC): A systematic review of clinical trials.
Jaime-Casas S, Zugman M, Barragan-Carrillo R, Zang P, Ebrahimi H, Mercier B, Castro D, Yip W, Li X, Dizman N, Salgia N, Hsu J, Nguyen C, Chehrazi-Raffle A, Zengin Z, Meza L, Pal S, Tripathi A. Efficacy and toxicity profile of antibody-drug conjugate (ADC) based combination therapy in patients with advanced urothelial carcinoma (aUC): A systematic review of clinical trials. Journal Of Clinical Oncology 2025, 43: 813-813. DOI: 10.1200/jco.2025.43.5_suppl.813.Peer-Reviewed Original ResearchAny-grade adverse eventsAdvanced urothelial carcinomaObjective-response rateAntibody-drug conjugatesCombination regimensClinical trialsCheckpoint inhibitorsSafety/tolerability profileCombination therapyPublished prospective clinical trialsProspective clinical trialPeer-reviewed clinical trialsSystematic review of clinical trialsReview of clinical trialsRandom-effects modelEnfortumab vedotinSacituzumab govitecanUrothelial carcinomaProspective trialsTreatment landscapeMaculopapular rashEfficacy outcomesRetrospective studyToxicity profileCase report
2024
Diagnostic performance of neural network algorithms in skull fracture detection on CT scans: a systematic review and meta-analysis
Sharifi G, Hajibeygi R, Zamani S, Easa A, Bahrami A, Eshraghi R, Moafi M, Ebrahimi M, Fathi M, Mirjafari A, Chan J, Dixe de Oliveira Santo I, Anar M, Rezaei O, Tu L. Diagnostic performance of neural network algorithms in skull fracture detection on CT scans: a systematic review and meta-analysis. Emergency Radiology 2024, 32: 97-111. PMID: 39680295, DOI: 10.1007/s10140-024-02300-7.Peer-Reviewed Original ResearchConceptsConvolutional neural networkArea under the receiver operating characteristic curveConvolutional neural network modelCT scanSkull fractureComputed tomographyDeep learningProspective clinical trialMeta-analysisReceiver operating characteristic curvePublication biasSkull fracture detectionSystematic reviewNeural network algorithmDetecting skull fracturesImprove diagnosis accuracyDiagnostic hurdlesShortage of radiologistsAutomated diagnostic toolTransfer learningDiagnostic performanceDiagnostic accuracyClinical trialsModel architectureNeural networkSaturday, July 13, 202411:30 AM - 12:30 PMGSOR01 Presentation Time: 11:30 AM A Prospective Clinical Trial Assessing Comfort of Brachytherapy with a Novel Tapered Vaginal Applicator
Mahal A, Yu J, Mahal R, Tien C, Adefres B, Damast S. Saturday, July 13, 202411:30 AM - 12:30 PMGSOR01 Presentation Time: 11:30 AM A Prospective Clinical Trial Assessing Comfort of Brachytherapy with a Novel Tapered Vaginal Applicator. Brachytherapy 2024, 23: s72-s73. DOI: 10.1016/j.brachy.2024.08.099.Peer-Reviewed Original ResearchVisual-analogue-scaleVaginal brachytherapyVaginal stretchingVaginal applicationEndometrial cancerAssociated with less painIr-192 seedsDose fall-offClinically significant responseProspective clinical trialPatient-centered evaluationVaginal introitusProspective trialsDose distributionSurface doseVaginal mucosaIr-192Less painNarrow introitusPaired t-testEC patientsConsenting patientsClinical trialsIntroitusPatientsInterventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma.
Bitar R, Salem R, Finn R, Greten T, Goldberg S, Chapiro J. Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma. Radiology 2024, 313: e232875. PMID: 39560477, PMCID: PMC11605110, DOI: 10.1148/radiol.232875.Peer-Reviewed Original ResearchConceptsManagement of hepatocellular carcinomaHepatocellular carcinomaLocoregional therapyClinical trialsImage-guided locoregional therapiesEnd pointsStages of hepatocellular carcinomaTumor microenvironment mechanismsCatheter-directed therapyCombination of immunotherapyProspective clinical trialImaging end pointsStandard of careAdjuvant settingNovel immunotherapiesCombination therapyTherapy resistanceInterventional radiologistsImmunotherapyDisease stageTherapyDisease evolutionNovel biomarkersCarcinomaMicroenvironment mechanismsInternational Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma
Binkley M, Flerlage J, Savage K, Akhtar S, Steiner R, Zhang X, Dickinson M, Prica A, Major A, Hendrickson P, Hopkins D, Ng A, Casulo C, Baron J, Roberts K, Al Kendi J, Balogh A, Ricardi U, Torka P, Specht L, De Silva R, Pickard K, Blazin L, Henry M, Smith C, Halperin D, Brady J, Brennan B, Senchenko M, Reeves M, Hoppe B, Terezakis S, Talaulikar D, Picardi M, Kirova Y, Fergusson P, Hawkes E, Lee D, Doo N, Barraclough A, Cheah C, Ku M, Hamad N, Mutsando H, Gilbertson M, Marconi T, Viiala N, Maurer M, Eichenauer D, Hoppe R, Borchmann P, Fuchs M, Hartmann S, Eich H, Lo A, Skinnider B, Rauf M, Maghfoor I, Pinnix C, Milgrom S, Vega F, Alomari M, Collins G, Advani R, Metzger M, Wirth A, Tsang R, Smith S, Kelsey C, McKay P, Koenig J, Constine L, Sakthivel K, Plastaras J, Gao S, Al Rahbi N, Levis M, Sridhar A, Shah N, Osborne W, Chang I, Miall F, Mikhaeel G, Penn A, Volchkov E, Della Pepa R, Northend M, Opat S, Salvaris R, Tedjaseputra A, Palese M, Shankar A, Natkunam Y, Kelly K. International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma. Journal Of Clinical Oncology 2024, 42: 2271-2280. PMID: 38531001, DOI: 10.1200/jco.23.01655.Peer-Reviewed Original ResearchNodular lymphocyte-predominant Hodgkin lymphomaProgression-free survivalLymphocyte-predominant Hodgkin lymphomaInternational Prognostic ScoreImmunoarchitectural patternsOverall survivalHodgkin lymphomaPrognostic scoreSplenic involvementAssociated with worse progression-free survivalAssociated with progression-free survivalDe-escalation of therapyMedian follow-upAge of patientsProspective clinical trialHigh-risk patientsStage III-IVClinical risk factorsRisk of transformationStage I to IIB symptomsAdult patientsIII-IVActive surveillanceRare cancers
2023
Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma
Tringale K, Wolden S, Karajannis M, Haque S, Pasquini L, Yildirim O, Rosenblum M, Benhamida J, Cheung N, Souweidane M, Basu E, Pandit-Taskar N, Zanzonico P, Humm J, Kramer K. Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma. Journal Of Neuro-Oncology 2023, 162: 69-78. PMID: 36853490, PMCID: PMC10050019, DOI: 10.1007/s11060-022-04235-w.Peer-Reviewed Original ResearchConceptsExternal beam radiotherapyCompartmental radioimmunotherapyOverall survivalCraniospinal axisBeam radiotherapyRecurrent medulloblastomaCases of radiation necrosisAssociated with progression-freeRecurrent primary brain tumorsCases of radionecrosisImprove survival outcomesMedium follow-upProspective clinical trialKaplan-Meier analysisPredictors of responseExtent of diseasePatterns of failurePrimary brain tumorNED statusUpfront therapyProgression-freeRadiation necrosisConclusionFor patientsEpendymoma patientsMultimodal therapy
2022
PRECISE CURATE.AI: A prospective feasibility trial to dynamically modulate personalized chemotherapy dose with artificial intelligence.
Blasiak A, Truong A, Jeit L, Kumar K, Tan S, Teo C, Tan B, Tadeo X, Tan L, Chee C, Yong W, Ho D, Sundar R. PRECISE CURATE.AI: A prospective feasibility trial to dynamically modulate personalized chemotherapy dose with artificial intelligence. Journal Of Clinical Oncology 2022, 40: 1574-1574. DOI: 10.1200/jco.2022.40.16_suppl.1574.Peer-Reviewed Original ResearchStandard-of-careSingle-agent capecitabineCapecitabine doseProspective feasibility trialClinical trialsChemotherapy doseSolid tumorsImprove patient response ratesDosing decisionsTreatment of solid tumorsIndividualize chemotherapy dosingAdvanced solid tumorsProspective clinical trialPatient response rateRandomized clinical trialsPrescribed dosePatient-specific variationsOpen-labelDosing recommendationsTumor markersOrgan dysfunctionPatient comorbiditiesDose selectionOncological indicationsCapecitabineUtilization of nano-hmC-seal technology to detect epigenetic signatures of peritoneal metastasis in cell-free DNA (cfDNA) in patients with colorectal and high-grade appendiceal cancer.
Dhiman A, Malina Y, Gao L, West-Szymanski D, Rivas M, Cui X, Witmer H, Berger Y, Ulrich L, Dougherty U, Kwesi A, Zhang W, He C, Bissonnette M, Turaga K. Utilization of nano-hmC-seal technology to detect epigenetic signatures of peritoneal metastasis in cell-free DNA (cfDNA) in patients with colorectal and high-grade appendiceal cancer. Journal Of Clinical Oncology 2022, 40: e15510-e15510. DOI: 10.1200/jco.2022.40.16_suppl.e15510.Peer-Reviewed Original ResearchCell-free DNAHigh-grade appendicealPeritoneal metastasisDetection of peritoneal metastasesHigh-grade appendiceal cancerLevels of cell-free DNALower GI cancersCurative-intent resectionCurative intent resectionProspective clinical trialMultivariate logistic modelAppendiceal cancerPeritoneal recurrenceIntent resectionMucinous tumorsPeritoneal diseaseDetect recurrenceGI tumorsPM patientsGI cancersEpigenetic mark 5-hydroxymethylcytosineMultivariable adjustmentClinical trialsMetastasisTumorThe role of renal contour change in the diagnosis of cortical scarring after urinary tract infection.
Muniz G, Charron M, Lim R, Shammas A, Liu H, Shaikh N. The role of renal contour change in the diagnosis of cortical scarring after urinary tract infection. American Journal Of Nuclear Medicine And Molecular Imaging 2022, 12: 41-43. PMID: 35295886, PMCID: PMC8918400.Peer-Reviewed Original ResearchUrinary tract infectionRenal scarringTract infectionsRenal contourDiagnosis of renal scarringPermanent renal scarringProspective clinical trialFollow-up scansNuclear medicine physiciansTechnetium-99mPresence of abnormalitiesRIVUR studyContour abnormalitiesCortical scarringClinical trialsTechnetium-99Medicine physiciansGold standardEligibility criteriaScarsContour changesAbnormalitiesDiagnosisInfectionChildren
2021
Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer
Rodrigues Pessoa R, Mueller A, Boxley P, Flaig T, Piper C, Konety B, Yu J, Gershman B, Kukreja J, Kim S. Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer. Urologic Oncology Seminars And Original Investigations 2021, 39: 786.e1-786.e8. PMID: 33846085, DOI: 10.1016/j.urolonc.2021.03.009.Peer-Reviewed Original ResearchConceptsHigh-risk non-muscle invasive bladder cancerNon-muscle invasive bladder cancerCancer specific-survivalRecurrence-free survivalInvasive bladder cancerBacillus Calmette-GuerinOverall survivalRadiation therapyBladder cancerMeta-analysisRates of recurrence-free survivalClinical trialsGoal of bladder preservationMetastatic disease rateSalvage radical cystectomyCochrane Central Register of Controlled TrialsProspective clinical trialCentral Register of Controlled TrialsTreatment of patientsRegister of Controlled TrialsSystematic reviewCochrane Central RegisterLow-quality evidenceQuality of evidenceBladder preservation
2020
657 Interleukin-6 receptor blockade for management of immune checkpoint inhibitor related adverse events in patients with melanoma
Saberian C, Fa’ak F, Tayar J, Buni M, Kim S, Lu H, Suarez-Almazor M, Gruschkus S, Daher M, Ludford K, Johnson D, Abdel-Wahab N, Diab A. 657 Interleukin-6 receptor blockade for management of immune checkpoint inhibitor related adverse events in patients with melanoma. Journal For ImmunoTherapy Of Cancer 2020, 8: a394-a394. DOI: 10.1136/jitc-2020-sitc2020.0657.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsIL-6R blockadeEfficacy of immune checkpoint inhibitorsMedian timeAdverse eventsIL-6RAnti-programmed cell death-1 antibodyImmune checkpoint inhibitor infusionsImmune mediated adverse eventsOverall tumor response ratePre-existing autoimmune diseaseInterleukin-6Interleukin-6 receptor blockadeClinical Disease Activity IndexICI-treated patientsTumor response rateMedian CRP levelsProspective clinical trialMinimal disease activityRelated adverse eventsDisease activity indexIrAE managementCheckpoint inhibitorsInterleukin-6 receptorMedian dose
2017
Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer
Galsky M, Shahin M, Jia R, Shaffer D, Gimpel-Tetra K, Tsao C, Baker C, Leiter A, Holland J, Sablinski T, Mehrazin R, Sfakianos J, Acon P, Oh W. Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer. JCO Clinical Cancer Informatics 2017, 1: 1-10. PMID: 30657386, DOI: 10.1200/cci.17.00044.Peer-Reviewed Original ResearchConceptsClinical trialsProstate cancerAdverse eventsSerum prostate-specific antigenStudy visitsClinical trials of metforminProstate-specific antigenTrial of metforminProspective clinical trialLocal therapySlow accrualOncology clinical trialsOral metforminStudy treatmentAnticancer activityTelehealth video visitsPatientsQuality of lifeSecondary objectivesPatient satisfactionCancerMetforminProstateTrial participantsTrialsTelemedicine-enabled clinical trial of metformin in patients (pts) with biochemically-recurrent prostate cancer (PCa).
Galsky M, Shahin M, Olson A, Shaffer D, Gimpel-Tetra K, Tsao C, Baker C, Leiter A, Holland J, Sablinski T, Mehrazin R, Sfakianos J, Acon P, Oh W. Telemedicine-enabled clinical trial of metformin in patients (pts) with biochemically-recurrent prostate cancer (PCa). Journal Of Clinical Oncology 2017, 35: 243-243. DOI: 10.1200/jco.2017.35.6_suppl.243.Peer-Reviewed Original ResearchProstate cancerAdverse eventsClinical trialsClinical trials of metforminTelemedicine visitsQuality of lifeGleason score 7Trial of metforminProspective clinical trialAnti-PCa activityCourse of metforminPSA riseRising PSAPSA changesLocal therapySlow accrualClinical trial sitesMedian ageOncology clinical trialsMonth courseScore 7Disease progressionPSASecondary objectivesMetformin
2014
Regional Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Potential Role for Dynamic Magnetic Resonance Imaging as an Imaging Biomarker and a Survival Update from Two Prospective Clinical Trials
Konstantinidis I, Do R, Gultekin D, Gönen M, Schwartz L, Fong Y, Allen P, D’Angelica M, DeMatteo R, Klimstra D, Kemeny N, Jarnagin W. Regional Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Potential Role for Dynamic Magnetic Resonance Imaging as an Imaging Biomarker and a Survival Update from Two Prospective Clinical Trials. Annals Of Surgical Oncology 2014, 21: 2675-2683. PMID: 24664624, PMCID: PMC4516216, DOI: 10.1245/s10434-014-3649-y.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBile Duct NeoplasmsBile Ducts, IntrahepaticBiomarkers, TumorCholangiocarcinomaDexamethasoneFemaleFloxuridineFollow-Up StudiesHumansInfusions, Intra-ArterialMagnetic Resonance ImagingMaleMiddle AgedNeoplasm StagingPrognosisProspective StudiesRetrospective StudiesSurvival RateConceptsUnresectable intrahepatic cholangiocarcinomaHepatic arterial infusionIntrahepatic cholangiocarcinomaDCE-MRIMagnetic resonance imagingMedian hepatic progression-free survivalClinical trialsHepatic progression-free survivalContrast-enhanced magnetic resonance imagingDynamic contrast-enhanced magnetic resonance imagingProgression-free survivalResponse Evaluation CriteriaAdvanced intrahepatic cholangiocarcinomaResonance imagingDied of diseaseResultsForty-four patientsProspective clinical trialPre-treatment DCE-MRILong-term outcomesDynamic magnetic resonance imagingSurvival updateStable diseasePartial responseMedian survivalRegional chemotherapy
2013
Is prostate cancer changing?: Evolving patterns of metastatic castration‐resistant prostate cancer
Doctor S, Tsao C, Godbold J, Galsky M, Oh W. Is prostate cancer changing?: Evolving patterns of metastatic castration‐resistant prostate cancer. Cancer 2013, 120: 833-839. PMID: 25302607, DOI: 10.1002/cncr.28494.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerPattern of metastasisProstate cancerNonosseous metastasesMetastatic diseaseClinical trialsAmerican Society of Clinical Oncology abstractsSite of metastatic diseaseRate of lymph node metastasisPattern of metastatic diseaseClinical trials of patientsSite of metastasisProspective clinical trialLymph node metastasisTrial of patientsOsseous metastasesLung metastasesNode metastasisBaseline characteristicsEvaluate temporal trendsOncology abstractsMetastasisTherapeutic studyTreatment selectionProgression of native coronary artery disease measured by intravascular ultrasound: systematic review and meta-analysis
Nascimento B, Sousa M, Chamie D, Demarqui F, Marcolino M, Ribeiro A, Costa M. Progression of native coronary artery disease measured by intravascular ultrasound: systematic review and meta-analysis. European Heart Journal 2013, 34: p3953. DOI: 10.1093/eurheartj/eht309.p3953.Peer-Reviewed Original ResearchFU timePlaque progressionStudy armsIntravascular ultrasoundResponse to specific therapiesControl armPlaque volume changesProgression of native coronary artery diseaseProspective clinical trialAnalysis of pooled dataNative coronary artery diseaseCoronary plaque progressionCoronary artery diseasePrevent progression of atherosclerosisEvaluate plaque progressionHigh-risk populationCombination of MeSH termsPlaque volume progressionRelevant risk factorsProgression of atherosclerosisStatin trialsSpecific therapiesUnivariate analysisPlaque regressionMEDLINE searchEvolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011.
Doctor S, Tsao C, Godbold J, Galsky M, Oh W. Evolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011. Journal Of Clinical Oncology 2013, 31: 5015-5015. DOI: 10.1200/jco.2013.31.15_suppl.5015.Peer-Reviewed Original ResearchCastration-resistant prostate cancerNon-osseous metastasesPattern of metastatic diseaseMetastatic CRPCMetastatic diseaseProportion of patientsClinical trialsLymph nodesMetastatic castration-resistant prostate cancerSoft tissue metastatic diseaseSite of metastatic diseaseClinical presentation of patientsIncreasing proportion of patientsIncreased lymph nodesSoft tissue metastasesSite of metastasisDemographic dataProspective clinical trialPresentation of patientsBaseline demographic dataTissue metastasesASCO abstractsLiver metastasesProstate cancerClinical presentationEvolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011.
Oh W, Doctor S, Godbold J, Galsky M, Tsao C. Evolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011. Journal Of Clinical Oncology 2013, 31: 195-195. DOI: 10.1200/jco.2013.31.6_suppl.195.Peer-Reviewed Original ResearchCastration-resistant prostate cancerNon-osseous metastasesPattern of metastatic diseaseMetastatic CRPCMetastatic diseaseProportion of patientsClinical trialsLymph nodesMetastatic castration-resistant prostate cancerSoft tissue metastatic diseaseSite of metastatic diseaseClinical presentation of patientsIncreased lymph nodesIncreasing proportion of patientsSoft tissue metastasesDemographic dataSite of metastasisPresentation of patientsProspective clinical trialBaseline demographic dataTissue metastasesASCO abstractsLiver metastasesProstate cancerClinical presentation
2011
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
Galsky M, Hahn N, Rosenberg J, Sonpavde G, Hutson T, Oh W, Dreicer R, Vogelzang N, Sternberg C, Bajorin D, Bellmunt J. Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy. Journal Of Clinical Oncology 2011, 29: 2432-2438. PMID: 21555688, DOI: 10.1200/jco.2011.34.8433.Peer-Reviewed Original ResearchConceptsMetastatic urothelial carcinomaUrothelial carcinomaChemotherapeutic regimensNew York Heart Association class III heart failureResults of prospective clinical trialsEastern Cooperative Oncology Group performance statusClinical trialsCisplatin-based combination chemotherapyClass III heart failureMetastatic urothelial cancerCisplatin-based chemotherapyIII heart failurePhase II trialPhase III trialsFirst-line treatmentProspective clinical trialSubgroup of patientsProportion of patientsTreatment of patientsCombination chemotherapyUniform definitionII trialIII trialsHearing lossUrothelial cancer
2009
Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials
Regan M, O'Donnell E, Kelly W, Halabi S, Berry W, Urakami S, Kikuno N, Oh W. Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. Annals Of Oncology 2009, 21: 312-318. PMID: 19633053, PMCID: PMC2852201, DOI: 10.1093/annonc/mdp308.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerProstate-specific antigenProstate cancerManagement of castration-resistant prostate cancerDisease characteristicsAssociated with prolonged survivalPost-therapy declineSingle-agent activityTaxane-based chemotherapyLeukemia Group BProspective clinical trialNomogram-predicted survivalAssociated with survivalIndividual patient dataPSA responseOverall survivalPrognostic factorsProlonged survivalBaseline to deathPooled analysisGroup BCox regressionChemotherapyPredicted survival probabilitiesClinical activity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply